Real Clinical Effectiveness of Molnupiravir Against 30-day Mortality Among 74 541 SARS-CoV-2–Positive Patients: A Nationwide Cohort Study From the Czech Republic
In this cohort study, early initiation of molnupiravir was associated with a significant reduction in 30-day all-cause and COVID-19-related mortality in adult SARS-CoV-2 positive patients.
Authors
- Ladislav Dušek (ORCID: https://orcid.org/0000-0002-8589-4378)
- Pavel Dlouhý
- Tomáš Pavlík (ORCID: https://orcid.org/0000-0001-7166-032X)
- Jiří Jarkovský (ORCID: https://orcid.org/0000-0002-1400-0111)
- Petr Štourač (ORCID: https://orcid.org/0000-0003-1944-5926)
- Vlastimil Válek (ORCID: https://orcid.org/0000-0002-1593-0142)
- Martina Vašáková (ORCID: https://orcid.org/0000-0002-0424-9941)
- Ondřej Šanca
- Vladimír Černý (ORCID: https://orcid.org/0000-0003-0834-7650)
Institutions
- Charles University (CZ)
- Masaryk University (CZ)
- Ministry of Health (CZ)
- University Hospital Brno (CZ)
- Institute of Health Information and Statistics (CZ)
- Thomayer University Hospital (CZ)
Publication Details
- Journal
- Open Forum Infectious Diseases
- Published
- 2024-11-19
- DOI
- https://doi.org/10.1093/ofid/ofae685
- Citations
- 1
- Primary Topic
- SARS-CoV-2 and COVID-19 Research
- Type
- article
- Field-Weighted Citation Impact
- 0.39
Funders
- Ministry of Higher Education and Scientific Research
- Systemic Risk Centre